Drug Royalty Announces New Director Dr. Calvin R. Stiller.TORONTO--(BUSINESS WIRE)--Nov. 12, 1996--DRUG ROYALTY CORPORATION INC. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : DRI) is pleased to announce the appointment of Dr. Calvin R. Stiller, C.M., M.D., F.R.C.P.(C) to its Board of Directors. Dr. Stiller is Chair and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of the Canadian Medical Discoveries Fund, which recently made a $7.5 million investment in Drug Royalty. "Dr. Stiller has a most distinguished medical and professional background, and we are exceptionally fortunate to have him on our Board", stated Edward Rygiel, Chairman of the Board and Chief Executive Officer of Drug Royalty. Dr. Stiller is one of Canada's preeminent medical figures. He is currently Professor in the Department of Medicine at the University of Western Ontario Western is one of Canada's leading universities, ranked #1 in the Globe and Mail University Report Card 2005 for overall quality of education.[2] It ranked #3 among medical-doctoral level universities according to Maclean's Magazine 2005 University Rankings. and is Co-Director of the Immunology Group at the John P. Robarts Research Institute The Robarts Research Institute is a non-profit medical research facility in London, Ontario, Canada with a staff of more than 600 people. Robarts scientists include physicians and physicists, biologists and biomedical engineers, and the range of diseases they study include heart . He established the Multi-Organ Transplant Service Multi-organ transplant service coordinates organ donation and patient management.[1] References 1. ^ [1] at University Hospital in London, Ontario, one of the first in the world and the first in Canada, and served as Chief from 1984-1996. He was Principal Investigator of the Canadian multi-centre study that demonstrated the benefit of Cyclosporine in transplantation which led to world-wide use of this therapy for transplant rejection. He led the Canadian-European team which first demonstrated in humans that juvenile diabetes was an immunological disorder which could be arrested by an immunosuppressive agent. Dr. Stiller served on the Council and executive of the Medical Research Council of Canada, and has held numerous other professional and government Dr. Stiller also brings to Drug Royalty, outstanding business experience. He was Chairman and founder of Diversicare Corporation, founder and currently Chairman of Chelsey Corporation, Oracle Service Network Corporation and Medical Discovery Management Corporation. He serves on the Board of London & Midland Insurance Company (a Textron subsidiary), the Advisory Board of Biotransplant Inc. (Boston), the Board of Biocoll and is a consultant to several multi-national corporations. Dr. Stiller has published over 265 scientific and medical papers, co-edited five books, authored the book, Lifegifts and is on five editorial boards. He was appointed the Royal College Lecturer in 1986 and 1988 by the Committee on Awards of the Royal College of Physicians and Surgeons of Canada The Royal College of Physicians and Surgeons of Canada, (RCPSC) is a national, private, nonprofit organization established in 1929 by a special Act of Parliament to oversee the medical education of specialists in Canada. . He was the recipient of the MEDEC Award of Canada (1992), the first Distinguished Scientist Award for International Medical Contributions from the University of Saskatchewan The University of Saskatchewan (U of S) is a coeducational public research university located on the east side of the South Saskatchewan River in Saskatoon, Saskatchewan, Canada. The University is celebrating its centennial year in 2007. (1993), the President's Merit Award of the Medical Research Council of Canada (1995) and is a Member of the Order of Canada The Order of Canada is Canada's highest civilian honour within the Canadian system of honours, with membership awarded to those who exemplify the Order's Latin motto Desiderantes meliorem patriam, which means "(those) desiring a better country" (Hebrews 11:16). (1995). Drug Royalty Corporation Inc. provides shareholders with a means of participating in the global pharmaceutical industry by acquiring royalty rights in emerging and existing drugs and medical technologies. Drug Royalty's common shares trade on The Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol DRI. CONTACT: Drug Royalty Corporation Jim Webster, 416/863-1865 416/863-5161 (FAX) or Drug Royalty Corporation Harry Loveys, 416/863-1865 416/863-5161 (FAX) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion